Abstract:The Keap1 (Kelch-like ECH-associated protein 1)-Nrf2 (nuclear factor erythroid 2-related factor 2)-ARE (antioxidant response element) pathway is the major defending mechanism against oxidative stresses, and directly disrupting the Keap1-Nrf2 protein–protein interaction (PPI) has been an attractive strategy to target oxidative stress-related diseases, including cardiovascular diseases. Here, we describe the design, synthesis, and structure–activity relationships (SARs) of indoline-based compounds as potent Keap1-Nrf2 PPI inhibitors. Comprehensive SAR analysis and thermodynamics-guided optimization identified 19a as the most potent inhibitor in this series, with an IC50 of 22 nM in a competitive fluorescence polarization assay. Further evaluation indicated the proper drug-like properties of 19a. Compound 19a dose-dependently upregulated genes and protein level of Nrf2 as well as its downstream markers and showed protective effects against lipopolysaccharide-induced injury in both H9c2 cardiac cells and mouse models. Collectively, we reported here a novel indoline-based Keap1-Nrf2 PPI inhibitor as a potential cardioprotective agent.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01116?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01116</a>.Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01116/suppl_file/jm0c01116_si_001.csv">CSV</a>)Characterization of the representative intermediates, characterization of the target compounds, Keap1 Kelch domain expression and purification, FP competition assay, binding mode of compound 15 with Keap1, determination of thermodynamic data based on tracer displacement assay, ITC assay, BLI assay, ARE-luciferase activity assay, cell viability assay, RNA extraction and qRT-PCR analysis, Western blot analysis, IL-1β, IL-6, and TNF-α production, evaluation of GSH/GSSG ratio, detection of ROS level, animal experiments, statistical analysis and 1H NMR, 13C NMR, HRMS and HPLC spectra for representative target compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01116/suppl_file/jm0c01116_si_002.pdf">PDF</a>)This article has not yet been cited by other publications.

Imidazo[1,2‐a]pyridine Derivatives as AMPK Activators: Synthesis, Structure–Activity Relationships, and Regulation of Reactive Oxygen Species in Renal Fibroblasts

Crocin Inhibited Epithelial-Mesenchymal Transition in Renal Tubular Epithelial Cells to Treat Diabetic Nephropathy Through Improving AMPK/mTOR-Mediated Autophagy

Synthesis, anticancer evaluation and in silico studies of novel N‐substituted arylidenethiazolidine‐2,4‐dione derivatives as adenosine monophosphate‐activated protein kinase activators

Design, Synthesis and Biological Evaluation of 6-(Nitroimidazole-1h-alkyloxyl)-4-anilinoquinazolines As Efficient EGFR Inhibitors Exerting Cytotoxic Effects Both under Normoxia and Hypoxia.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-a]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors.

Design, Synthesis, and Biological Evaluation of Imidazo[1,2-<i>a</i>]pyridine Derivatives as Novel PI3K/mTOR Dual Inhibitors

Design, Synthesis and Biological Evaluation of 4,7,12,12A-Tetrahydro-5h-thieno[3',2':3,4]Pyrido[1,2-b]isoquinolines As Novel Adenosine 5'-Monophosphate-activated Protein Kinase (AMPK) Indirect Activators for the Treatment of Type 2 Diabetes.

Design, Synthesis, and Biological Study of 4-[(2-nitroimidazole-1h-alkyloxyl)aniline]-quinazolines As EGFR Inhibitors Exerting Cytotoxicities Both under Normoxia and Hypoxia.

Chromone Derivatives as a Novel NOX4 Inhibitor: Design, Synthesis, and Regulation of ROS in Renal Fibroblast

Computer-aided drug design for AMP-activated protein kinase activators.

AMPK: An Emerging Drug Target for Diabetes and the Metabolic Syndrome

Small molecule QF84139 ameliorates cardiac hypertrophy via activating the AMPK signaling pathway

In Silico Design for Adenosine Monophosphate-Activated Protein Kinase Agonist from Traditional Chinese Medicine for Treatment of Metabolic Syndromes.

Computational screening and QSAR analysis for design of AMP-activated protein kinase agonist

Design, Synthesis and Pharmacological Evaluation of Naphthofuran Derivatives as Potent SIRT1 Activators

Drug Design for AMP-Activated Protein Kinase Agonists in Silico

HL156A, a novel pharmacological agent with potent adenosine-monophosphate-activated protein kinase (AMPK) activator activity ameliorates renal fibrosis in a rat unilateral ureteral obstruction model

Discovery of natural adenosine monophosphate‐activated protein kinase activators through virtual screening and activity verification studies

Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK.

Study of Amp-Activated Protein Kinase Agonists by Structure-Based Drug Designing

Design, Synthesis, and Structure–Activity Relationships of Indoline-Based Kelch-like ECH-Associated Protein 1-Nuclear Factor (Erythroid-Derived 2)-Like 2 (Keap1-Nrf2) Protein–Protein Interaction Inhibitors